Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation.

Noro R, Seike M, Zou F, Soeno C, Matsuda K, Sugano T, Nishijima N, Matsumoto M, Kitamura K, Kosaihira S, Minegishi Y, Yoshimura A, Kubota K, Gemma A.

BMC Cancer. 2015 Feb 6;15:31. doi: 10.1186/s12885-015-1019-1.

2.

Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation.

Miyanaga A, Shimizu K, Noro R, Seike M, Kitamura K, Kosaihira S, Minegishi Y, Shukuya T, Yoshimura A, Kawamoto M, Tsuchiya S, Hagiwara K, Soda M, Takeuchi K, Yamamoto N, Mano H, Ishikawa Y, Gemma A.

BMC Cancer. 2013 May 29;13:262. doi: 10.1186/1471-2407-13-262.

3.

Alternating chemotherapy with amrubicin plus cisplatin and weekly administration of irinotecan plus cisplatin for extensive-stage small cell lung cancer.

Noro R, Yoshimura A, Yamamoto K, Miyanaga A, Mizutani H, Minegishi Y, Seike M, Kubota K, Kosaihira S, Hino M, Ando M, Nomura K, Okano T, Kobayashi K, Uematsu K, Gemma A; East Japan Chesters Group.

Anticancer Res. 2013 Mar;33(3):1117-23.

PMID:
23482789
4.

An effective training program for chest tube drainage for medical interns in a clinical simulation laboratory.

Yoshimura A, Kosaihira S, Morimoto T, Kim C, Tsueshita T, Adachi K, Aso R, Shimura T, Nakano H, Gemma A.

J Nippon Med Sch. 2012;79(6):403-8.

5.

Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion.

Kitamura K, Kubota K, Ando M, Takahashi S, Nishijima N, Sugano T, Toyokawa M, Miwa K, Kosaihira S, Noro R, Minegishi Y, Seike M, Yoshimura A, Gemma A.

Cancer Chemother Pharmacol. 2013 Feb;71(2):457-61. doi: 10.1007/s00280-012-2026-4. Epub 2012 Nov 21.

PMID:
23178954
6.

Combination chemotherapy of alternating etoposide and carboplatin with weekly administration of irinotecan and cisplatin in extensive-stage small-cell lung cancer.

Yoshimura A, Noro R, Miyanaga A, Mizutani H, Kosaihira S, Minegishi Y, Seike M, Hino M, Ando M, Nomura K, Okano T, Kobayashi K, Gemma A; East Japan Chesters Group.

Anticancer Res. 2012 Oct;32(10):4473-8.

PMID:
23060575
7.

The feasibility study of Carboplatin plus Etoposide for advanced small cell lung cancer with idiopathic interstitial pneumonias.

Minegishi Y, Kuribayashi H, Kitamura K, Mizutani H, Kosaihira S, Okano T, Seike M, Azuma A, Yoshimura A, Kudoh S, Gemma A.

J Thorac Oncol. 2011 Apr;6(4):801-7. doi: 10.1097/JTO.0b013e3182103d3c.

8.

Phase II study of nimustine hydrochloride (ACNU) plus paclitaxel for refractory small cell lung cancer.

Isobe K, Kobayashi K, Kosaihira S, Kurimoto F, Sakai H, Uchida Y, Nagai Y, Yamaguchi T, Miyanaga A, Ando M, Mori G, Hino M, Gemma A.

Lung Cancer. 2009 Dec;66(3):350-4. doi: 10.1016/j.lungcan.2009.03.003. Epub 2009 Apr 1.

PMID:
19342118
9.

E-cadherin expression and epidermal growth factor receptor mutation status predict outcome in non-small cell lung cancer patients treated with gefitinib.

Miyanaga A, Gemma A, Ando M, Kosaihira S, Noro R, Minegishi Y, Kataoka K, Nara M, Okano T, Miyazawa H, Tanaka T, Yoshimura A, Kobayashi K, Iwanami H, Hagiwara K, Tsuboi E, Kudoh S.

Oncol Rep. 2008 Feb;19(2):377-83.

PMID:
18202784
10.

PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors.

Noro R, Gemma A, Miyanaga A, Kosaihira S, Minegishi Y, Nara M, Kokubo Y, Seike M, Kataoka K, Matsuda K, Okano T, Yoshimura A, Kudoh S.

Int J Oncol. 2007 Nov;31(5):1157-63.

PMID:
17912443
11.

Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.

Noro R, Gemma A, Kosaihira S, Kokubo Y, Chen M, Seike M, Kataoka K, Matsuda K, Okano T, Minegishi Y, Yoshimura A, Kudoh S.

BMC Cancer. 2006 Dec 6;6:277.

12.

Phase I/II study of paclitaxel + carboplatin for refractory or recurrent non-small cell lung cancer.

Gemma A, Seike M, Kosaihira S, Minegishi Y, Noro R, Nara M, Hosomi Y, Okano T, Kokubo Y, Yoshimura A, Shibuya M, Kudoh S.

Anticancer Res. 2006 Jul-Aug;26(4B):3083-7.

13.

Anticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database.

Gemma A, Li C, Sugiyama Y, Matsuda K, Seike Y, Kosaihira S, Minegishi Y, Noro R, Nara M, Seike M, Yoshimura A, Shionoya A, Kawakami A, Ogawa N, Uesaka H, Kudoh S.

BMC Cancer. 2006 Jun 30;6:174.

Supplemental Content

Loading ...
Support Center